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ABCD2 risk score does not predict the
presence of cerebral microemboli in
patients with hyper-acute symptomatic
critical carotid artery stenosis
Mahmud Saedon,1 Charles E Hutchinson,1 Christopher H E Imray,1,2
Donald R J Singer1,3,4
ABSTRACT
Introduction: ABCD2 risk score and cerebral
microemboli detected by transcranial Doppler (TCD)
have been separately shown to the predict risk of
recurrent acute stroke. We studied whether ABCD2 risk
score predicts cerebral microemboli in patients with
hyper-acute symptomatic carotid artery stenosis.
Participants and methods: We studied 206 patients
presenting within 2 weeks of transient ischaemic attack
or minor stroke and found to have critical carotid
artery stenosis (≥50%). 86 patients (age 70±1 (SEM:
years), 58 men, 83 Caucasian) had evidence of
microemboli; 72 (84%) of these underwent carotid
endarterectomy (CEA). 120 patients (age 72±1 years,
91 men, 113 Caucasian) did not have microemboli
detected; 102 (85%) of these underwent CEA. Data
were analysed using X2 and Mann–Whitney U tests
and receiver operating characteristic (ROC) curves.
Results: 140/206 (68%: 95% CI 61.63 to 74.37)
patients with hyper-acute symptomatic critical carotid
stenosis had an ABCD2 risk score ≥4. There was no
significant difference in the NICE red flag criterion for
early assessment (ABCD2 risk score ≥4) for patients
with cerebral microemboli versus those without
microemboli (59/86 vs 81/120 patients: OR 1.05
ABCD2 risk score ≥4 (95% CI 0.58 to 1.90,
p=0.867)). The ABCD2 risk score was <4 in 27 of 86
(31%: 95% CI 21 to 41) embolising patients and in
39 of 120 (31%: 95% CI 23 to 39) without cerebral
microemboli. After adjusting for pre-neurological event
antiplatelet treatment (APT), area under the curve
(AUC) of ROC for ABCD2 risk score showed no
prediction of cerebral microemboli (no pre-event APT,
n=57: AUC 0.45 (95% CI 0.29 to 0.60, p=0.531); pre-
event APT, n=147: AUC 0.51 (95% CI 0.42 to 0.60,
p=0.804)).
Conclusions: The ABCD2 score did not predict the
presence of cerebral microemboli or carotid disease in
over one-quarter of patients with symptomatic critical
carotid artery stenosis. On the basis of NICE
guidelines (refer early if ABCD2 ≥4), assessment of
high stroke risk based on ABCD2 scoring may lead to
inappropriate delay in urgent treatment in many
patients.
INTRODUCTION
The risk of recurrent stroke following ﬁrst
transient ischaemic attack (TIA) or minor
stroke is highest during the ﬁrst 7–14 days.1
On the basis of evidence that the beneﬁt
of surgery is greatest if performed within
2 weeks after the last ischaemic event,2 the
major NICE clinical guideline recommends
that patients with symptomatic carotid artery
stenosis have urgent endarterectomy within
2 weeks.3
Transcranial Doppler (TCD)-detected
microemboli have provided direct evidence of
thromboembolism as the main mechanism
of symptomatic carotid artery disease.4 TCD-
detected cerebral microembolic signals (MES)
predict short-term stroke risk in patients with
symptomatic carotid stenosis.5–9
The ABCD2 risk prognostic scoring
system10 predicts who is likely to be at
increased risk of suffering a recurrent early
stroke following onset of an initial stroke/
TIA,10 irrespective of the mechanism for
acute stroke or TIA. The ABCD2 risk score is
based on standard cardiovascular risk factors,
including history of diabetes, in addition to
clinical features of carotid disease. Several
major clinical guidelines3 11 recommend that
patients with an ABCD2 risk score ≥4 should
be assessed within 24 hours and those with
an ABCD2 risk score <4 should be evaluated
within a week of symptoms onset.
ABCD2 risk score and the presence of cere-
bral microemboli predict risk of early recur-
rence of stroke. The association between
ABCD2 risk score and cerebral microemboli
has not been studied. We therefore aimed to
explore whether the ABCD2 risk score pre-
dicts the presence of cerebral microemboli
in patients with hyper-acute symptomatic crit-
ical carotid artery stenosis.
   41Saedon M, et al. Stroke and Vascular Neurology 2017;2:e000073. doi:10.1136/svn-2017-000073
Open Access 
1Warwick Medical School, 
University of Warwick, Coventry, 
UK
2University Hospitals Coventry 
Warwickshire NHS Trust, 
Coventry, UK
3Fellowship of Postgraduate 
Medicine, London, UK
4Yale School of Medicine, New 
Haven, Connecticut, USA
Correspondence to
Professor Donald RJ Singer;  
 fpm. chandos@ gmail. com
To cite: Saedon M, 
Hutchinson CE, Imray CHE, 
et al. ABCD2 risk score does 
not predict the presence of 
cerebral microemboli in patients 
with hyper-acute symptomatic 
critical carotid artery stenosis. 
Stroke and Vascular Neurology 
2017;2:e000073. doi:10.1136/
svn-2017-000073
CEH and CHEI are joint senior 
authors.
Received 23 January 2017
Accepted 2 February 2017
Published Online First 
17 March 2017
Original article
PARTICIPANTS AND METHODS
We determined ABCD2 scores in 206 patients (age 70±1
(SEM) years, men 149, Caucasian 196) with acutely
symptomatic critical carotid artery stenosis. A total of
102 patients were from our Carotid Registry of patients
who had undergone carotid endarterectomy (CEA)
between January 2002 and December 2010.12 A further
104 consecutive patients were recruited between January
2011 and May 2013 within a new prospective observa-
tional study of patients presenting with acutely symptom-
atic critical carotid artery stenosis. In this report, we
deﬁne the hyper-acute period as within 2 weeks of stroke
or TIA.13
Inclusion and exclusion criteria
All patients had presented within 2 weeks of symptoms
of acute non-disabling stroke (Modiﬁed Rankin Scale
(mRS) ≤2) or TIA. All had haemodynamically signiﬁ-
cant carotid artery stenosis of at least 50%14 measured
by carotid duplex scan based on NASCET criteria as
recommended by Vascular Society and the Society of
Vascular Technology of Great Britain and Ireland.15
Since 2002, it has been the policy in our centre for all
patients with hyper-acute symptomatic TIA or stroke to
have a TCD examination to detect cerebral microem-
boli, as this cohort of patients merits more aggressive
treatment to prevent recurrent stroke.16
We excluded patients with atrial ﬁbrillation, because
this confers risk of an additional non-carotid source of
emboli. We also excluded patients with a prosthetic
heart valve, because of the recognised effect of these
valves to generate gaseous and other embolic signals.17
We also excluded patients who had had a major stroke
or presented more than 2 weeks after the onset of
symptoms.
Assessment of the ABCD2 risk score
ABCD2 scores9 were available in all patients recruited for
the prospective observational study from 2011 to 2013.
Seven patients from the Carotid Surgery Registry from
the period of 2002 and 2005 were excluded from the
analysis due to lack of data pertinent to the ABCD2 risk
score calculation.
TCD recording
TCD monitoring18 was performed (PC Dop 842;
SciMed, Bristol, UK) with a 2 MHz probe focused on the
middle cerebral artery ipsilateral to the stenotic carotid
artery. The TCD signal was assessed by an experienced
vascular scientist. The middle cerebral artery (MCA) was
identiﬁed by placing the probe above the zygomatic
arch and just in front of the ear. A head-frame was used
to secure a constant angle of insonation during the TCD
monitoring. Doppler signals were obtained within the
depth range of 55–64 mm and time-averaged mean vel-
ocity in the region of 55±12 cm/s. We used a single
channel and a ﬁlter set to a low threshold to capture all
possible signals. The recorded ultrasonographic images
were then assessed to differentiate artefact from micro-
emboli, based on criteria of the International Consensus
Group on microembolus detection.18 MES were identi-
ﬁed as unidirectional, short duration signals (range 10–
100 ms) with intensity threshold above 6 dB, accompan-
ied by characteristic audible clicks and occurring ran-
domly throughout the cardiac cycle.18 19 Monitoring was
performed for 60 min after carotid duplex assessment.
Microembolic signals
On the basis of Markus et al,7 we used a dichotomous
outcome to classify patients with microembolic TIA or
stroke, according to MES presence rather than rate or
number of MES.
Ethics
The new prospective observational study was approved
by the NHS Ethics Committee (MREC number 10/
H1206/77) and Research & Development Department
(R&D C1080610). All patients included in the new pro-
spective observational study were consented. For the
Registry data, institutional approval was granted; the
Research & Development Department at University
Hospital Coventry and Warwickshire NHS Trust (host
institution) conﬁrmed that regional Research Ethics
Committee (REC) review was not required under the
harmonised Governance Arrangement for REC
(GAfREC) for research because this study was consid-
ered part of service evaluation (audit). Therefore,
patients’ consent was not required.
Statistical analyses
In view of differences among patients in antiplatelet
treatment (APT) prior to their acute neurological
events, we analysed the data in two stages. Initially, we
studied microembolic and non-microembolic cohorts
together. Then, taking into account the inﬂuence of
APT on cerebral microemboli,20 we analysed the data
separately for patients with or without pre-neurological
event antiplatelet or statin treatment.
Statistical analyses were conducted using SPSS V.19
(Chicago, Illinois, USA).
Parametric data are expressed as mean and SEM.
Non-parametric data are expressed as median and IQR.
Non-parametric unpaired data were analysed using the
Mann–Whitney U test for two group comparisons.
Categorical variables were analysed using the χ2 test or
Fisher’s exact test. Spearman’s rank correlation coefﬁ-
cient was used to assess the strength of relationship
between microemboli and ABCD2 risk score. The associ-
ation between microemboli and ABCD2 risk scores was
also analysed using receiver operating characteristic
(ROC) curves. A p value of <0.05 was considered
signiﬁcant.
Sample size calculation
We set an area under the curve (AUC) of 0.5 or below
as the cut-off point for ABCD2 score not predicting the
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presence of microemboli. For the whole group, the
study had 80% power at the 5% level in a two-tailed test
to detect at least 0.69 as AUC for ROC (71 participants
per group).
RESULTS
Clinical features
We included 206 patients (age 70±1 year, 149 men, 196
Caucasians) in this study. A total of 86 patients (age 70
±1, 58 men, 83 Caucasians) had evidence of microem-
boli; 72 (84%) of these underwent CEA. A single patient
had a TIA, one patient developed myocardial infarction
and one embolising patient died due to renal failure
30 days after CEA.
A total of 120 patients (age 72±1 years, 91 men, 113
Caucasians) did not have microemboli detected; 102
(85%) of these underwent CEA. APT had been pre-
scribed to 67 of 86 (78%) patients with microemboli,
and to 82 of 120 (68%) patients without microemboli
(p=0.130, X2) prior to the index neurological event.
The complications in the 30 days after CEA were TIA in
two patients, stroke in three patients and death in three
non-embolising patients (sepsis and haemorrhagic
strokes).
Family history of vascular disease was more common
in the non-embolising group (42 (35%)) than in those
who had microemboli following non-disabling stroke/
TIA (19(22%); OR 1.5 (95% CI 0.98 to 2.2); p=0.045,
table 1). Peripheral arterial disease was also more
common in the non-embolising group (21(18%)) com-
pared with those who had microemboli associated with
stroke or TIA (7(8%); OR 1.8 (95% CI 0.95 to 3.6),
p=0.038, tables 1 and 2). The microembolic stroke/TIA
cohort had a slightly higher level of total cholesterol
(4.9±0.2 mmol/L) than controls (4.5±0.1 mmol/L;
p=0.01, MW; table 2). Carotid ultrasound imaging
revealed no difference in degree of carotid artery
stenosis between those with versus those without micro-
emboli (microemboli: 80±1% vs controls: 79±1%;
p=0.845, MW test).
ABCD2 risk score
Of 206 patients 140 (68%: 95% CI 62% to 74%) patients
with hyper-acute symptomatic critical carotid stenosis
had an ABCD2 risk score ≥4. The ABCD2 risk score was
≥4 in 59 of 86 (69%: 95% CI 59% to 79%) embolising
patients and in 81 of 120 (68%: 95% CI 60 to 76)
without cerebral microemboli. There was no signiﬁcant
difference in the NICE criterion for early assessment
(ABCD2 risk score ≥4) for patients with cerebral micro-
emboli versus those without microemboli (59/86 vs 81/
120 patients: OR 1.05 (95% CI 0.58 to 1.90, p=0.867)).
Of 206 patients, 66 (32%: 95% CI 26 to 38) patients
with hyper-acute symptomatic critical carotid stenosis
had an ABCD2 risk score <4. The ABCD2 risk score was
<4 in 27 of 86 (31%: 95% CI 21 to 41) embolising
patients and in 39 of 120 (31%: 95% CI 23 to 39)
without cerebral microemboli.
There was no signiﬁcant ABCD2 score difference
between these two cohorts (non-embolising group,
n=120: ABCD2 score 4 (IQR 3–5) versus embolising
group, n=86: 4 (IQR 3–5), p=0.855 MW test). There was
no signiﬁcant ABCD2 score difference between Registry
patients and prospective cohort study patients (Registry,
n=102: ABCD2 score 4(IQR 3–5) versus prospective
cohort study, n=104: 4(IQR 3–5), p=0.661 MW test).
ROC for ABCD2 score to predict the presence of
microemboli
All 206 patients were included into this analysis: 120
patients without and 86 patients with microemboli. The
ROC for ABCD2 risk scores showed no signiﬁcant pre-
diction of microemboli (AUC 0.49, 95% CI 0.41 to 0.57,
p=0.860; ﬁgure 1).
Table 1 Demographic and clinical profile in patients with hyper-acute symptomatic carotid stenosis: 120 without microemboli
and 86 with microemboli
Non-embolising group
n (%)
Embolising group
n (%)
χ2 test
p Value
Age, mean±SEM 72±1 70±1 0.339
Male 91 (76) 58 (67) 0.184
Caucasian 113 (94) 83 (97) 0.290
South Asian 3 (2.5) (0)
Hypertension 93 (78) 65 (76) 0.748
Never smoked 42 (35) 28 (33) 0.655
Current smoker 46 (38) 30 (34)
Ex-smoker 32 (27) 28 (33)
Ischaemic heart disease 28 (23) 17 (20) 0.157
Type 2 diabetes mellitus 20 (17) 16 (19) 0.907
Hypercholesterolaemia 65 (54) 51 (59) 0.464
Peripheral arterial disease 22 (18) 7 (8) 0.038
Cerebrovascular disease 24 (20) 20 (23) 0.574
Family history 42 (35) 19 (22) 0.045
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Patients without APT before the neurological event
A total of 57 patients were included in this analysis, 19
of whom had evidence of microemboli and 38 patients
no evidence of microemboli. The ROC for ABCD2 risk
score showed no prediction of microemboli (AUC 0.45
(95% CI 0.30 to 0.60), p=0.531; ﬁgure 2A).
Patient with APT before the neurological event
A total of 149 patients were included in this analysis,
67 of whom had evidence of microemboli and
82 patients had no evidence of microemboli. The ROC
for ABCD2 risk score showed no prediction of
microemboli (AUC 0.51 (95% CI 0.42 to 0.60),
p=0.804: ﬁgure 2B).
Patients without statin treatment before the neurological
event
A total of 72 patients were included in this analysis, 31
of whom had evidence of microemboli and 41 had no
evidence of microemboli. The ROC for ABCD2 risk
score showed no prediction of microemboli (AUC 0.48
(95% CI 0.34 to 0.61), p=0.716).
Patient with statin treatment before the neurological event
A total of 134 patients were included in this analysis, 55
of whom had evidence of microemboli and 79 patients
had no evidence of microemboli. The ROC for ABCD2
risk score showed no prediction of microemboli (AUC
0.50 (95% CI 0.40 to 0.60), p=0.980).
DISCUSSION
In our study, the ABCD2 risk score was unable to identify
patients with cerebral microemboli associated with symp-
tomatic critical carotid artery stenosis. To the best of our
knowledge, this is the ﬁrst report to explore the possible
links between ABCD2 risk score and cerebral microem-
boli in patients with hyper-acute symptomatic critical
carotid artery stenosis. Taken together with previous
reports,5–9 our study provides important evidence that
the occurrence of cerebral microemboli, predictors of
stroke risk, is dissociated from the results for the ABCD2
risk score.
In our study, around one-third of the patients with
hyper-acute symptomatic carotid disease with or without
microemboli would not have been triaged effectively for
urgent management using the ABCD2 risk score alone.
Furthermore, almost a third of the patients with micro-
emboli with ABCD2 risk score <4 would not have been
assessed within 24 hours if NICE guidelines had been
followed.
Table 2 Blood pressure and preoperative laboratory values in patients with hyper-acute symptomatic carotid stenosis: 120
without microemboli and 86 with microemboli
Laboratory variables
Non-embolising group
Mean±SEM (n)
Embolising group
Mean±SEM (n)
Mann–Whitney U-test
p Value
Systolic blood pressure 151±2 (120) 152±3 (86) 0.88
Diastolic blood pressure 77±1 (120) 82±3 (86) 0.986
Cholesterol (mmol/L) 4.5±0.1 (102) 4.9±0.2 (66) 0.041
Triglyceride (mmol/L) 1.6±0.1 (56) 1.95±0.2 (41) 0.869
HDL (mmol/L) 1.37±0.1 (95) 1.46±0.1 (64) 0.697
Creatinine (μmol/L) 99±3 (120) 104±6 (51) 0.692
Glucose (mmol/L) 5.8±0.2 (97) 5.8±0.2 (56) 0.548
Haemoglobin (g/L) 137±12 (119) 134±02 (86) 0.133
Platelet (×109/L) 254±6 (119) 259±8 (86) 0.762
White cell count (×109/L) 8.2±0.2 (119) 8.1±0.3 (86) 0.418
CRP (mg/L) 7.4±2.0 (34) 7.8±1.3 (57) 0.954
HbA1C (%) 6.3±0.2 (19) 6.1±0.1 (12) 0.764
Carotid stenosis (%) 79±1 (86) 80±1 (86) 0.845
Figure 1 ROC for ABCD2 risk scores against the presence
of microemboli in patients (n=206) with hyper-acute
symptomatic carotid stenosis (AUC 0.49, 95% CI 0.41 to 0.57,
p=0.860). AUC, area under the curve; ROC, receiver
operating characteristic.
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Of note in our study, vascular complications were lower
in patients with MES. This is likely to be due to reverse
causality, as in our centre patients with microemboli were
assigned to receive more aggressive APT compared to
those in whom microemboli were not detected.16 21
Currently, the association between ABCD2 risk score
and severity of structural carotid artery disease is
unclear. This is an important issue to clarify as Ois et al22
reported that patients presenting with symptomatic crit-
ical carotid artery stenosis incur a 17% risk of recurrent
stroke at 72 hours, increasing to 22% at 7 days.22 While
Amarenco et al23 and Walker et al24 did not ﬁnd an asso-
ciation between ABCD2 risk score and carotid artery
disease, Schrock et al,25 Sheehan et al26 and Koton and
Rothwell27 suggested that high ABCD2 risk score may
identify patients with signiﬁcant carotid artery disease.
However, Amarenco et al23 reported that an ABCD2 risk
score < 4 would miss 9% (62/679) of patients with symp-
tomatic critical carotid artery stenosis.
The inadequacy of ABCD2 risk score alone for stratiﬁ-
cation of high risk of a recurrent event after a stroke or
TIA has been recognised by Merwick et al28 in an inter-
national multicentre observational study based on
pooled data from Europe and North America. Merwick
et al28 expanded the standard ABCD2 risk score to the
ABCD3-I risk score by including the presence of ≥2 TIA
within 7 days, critical carotid artery stenosis and acute
diffusion-weighted imaging hyperintensity lesion.
ABCD3-I risk scores were found to be better at stratifying
stroke risk than ABCD2 risk score in patients who had
stroke/TIA. In a more recent validation study in Japan,
the ABCD3-I risk score was found to be better at stratify-
ing stroke risk than ABCD2 risk score in patients who
had stroke or TIA.29 This ﬁnding should be expected as
patients with recent symptomatic carotid stenosis and
diffusion-weighted imaging were at least threefold
higher risk of stroke.28 However, diffusion-weighted
imaging and carotid imaging are only available at the
secondary care level, so this defeats the initial purpose
of applying the ABCD2 risk score for triage in the com-
munity. With additional carotid stenosis in the risk score
means that the carotid imaging should generally be per-
formed in all TIA/minor ischaemic patients who had
stroke as soon as possible. This is potentially problematic
in clinical settings with limited access to carotid imaging
(whether the patient is admitted or not). Another limita-
tion of studies by Merwick et al28 and Kiyohara et al29 was
that only 12% and 20% of patients, respectively, had
carotid disease in their studies.
Our study has major policy implications. In particular,
we have shown that the ABCD2 risk score, a widely used
and relied on score to guide stroke management, is ser-
iously ﬂawed in failing to detect many patients who had
high-risk carotid disease with or without microemboli.
The presence of microemboli is already a well-
established predictor of stroke,6 and treatment to sup-
press microemboli has been shown to reduce the rate of
recurrent stroke.20 It would therefore not have been
ethical to deprive patients identiﬁed as having microem-
boli from early active treatment.
CONCLUSIONS
Thus, on the basis of ABCD2 risk score alone, a signiﬁ-
cant minority of patients with hyper-acute symptomatic
carotid stenosis with or without cerebral microemboli
would be likely to be overlooked in triage for more
urgent assessment and thus exposed to delays in treat-
ment to preventable recurrent stroke.
Figure 2 (A) ROC for ABCD2 risk scores against the presence of microemboli in patients (n=57) without APT pre-neurological
event (AUC 0.45 (95% CI 0.30 to 0.60), p=0.531). (B) ROC for ABCD2 risk scores against the presence of microemboli in
patients (n=149) with APT pre-neurological event (AUC 0.51 (95% CI 0.43 to 0.60), p=0.531). APT, antiplatelet treatment; AUC,
area under the curve; ROC, receiver operating characteristic.
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